Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard.
Authors
Donohoe, Claire LO'Farrell, Naoimh J
Grant, Tim
King, Sinead
Clarke, Lindsey
Muldoon, Cian
Reynolds, John V
Affiliation
*Department of Surgery, Trinity Centre for Health Sciences, Trinity College Dublin, and St James Hospital †Department of Biostatistics, University College Dublin ‡Department of Pathology, St James Hospital, Dublin, Ireland.Issue Date
2013-11Keywords
CANCERLocal subject classification
CANCER, THERAPYSIDE EFFECTS
MeSH
AdenocarcinomaAdult
Aged
Carcinoma, Squamous Cell
Diagnostic Imaging
Esophageal Neoplasms
Esophagectomy
Esophagogastric Junction
Female
Humans
Lymphatic Metastasis
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Prospective Studies
Survival Rate
Treatment Outcome
Metadata
Show full item recordCitation
Donohoe CL et al. Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard. Ann. Surg. 2013, 258 (5):784-92; discussion 792Journal
Annals of surgeryDOI
10.1097/SLA.0b013e3182a66588PubMed ID
24045450Abstract
To assess existing measures of pathologic response to neoadjuvant therapy in esophageal and junctional cancer, and to recommend an optimum classification.Item Type
ArticleLanguage
enISSN
1528-1140ae974a485f413a2113503eed53cd6c53
10.1097/SLA.0b013e3182a66588
Scopus Count
Collections
Related articles
- Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
- Authors: Castoro C, Scarpa M, Cagol M, Ruol A, Cavallin F, Alfieri R, Zanchettin G, Rugge M, Ancona E
- Issue date: 2011 Dec
- Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
- Authors: Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM
- Issue date: 2008 Oct
- Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
- Authors: Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, Sharland DM, Rees CN, Iveson TJ, Underwood TJ, Bateman AR
- Issue date: 2013 Dec 28
- Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.
- Authors: Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL
- Issue date: 2010 Sep
- Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center.
- Authors: Reynolds JV, Donohoe CL, McGillycuddy E, Ravi N, O'Toole D, O'Byrne K, Hollywood D
- Issue date: 2012 May